Drugs / PF2020-CELL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05039411 | Mar 2022 → Dec 2026 expected | anal fistula, perianal Crohn disease | CryoCord Sdn Bhd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF2020-CELL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05039411 ↗ |
| Known as | UC-MSCs | “All patients will receive a total of 60 million PF2020-CELL (UC-MSCs) cells per treatment visit.” NCT05039411 ↗ |
| Modality | Cell therapy | “Allogeneic Human Umbilical Cord Mesenchymal Stem Cells” NCT05039411 ↗ |
| Route | Other | “will be injected locally around the fistula tract” NCT05039411 ↗ |